SCHEMBL6418364

SCHEMBL6418364

NN=C(c1cc(Cl)ccc1O)c1nc2nonc2nc1Nc1cccc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 1/20 0.43
P2RX1 P51575 1/20 0.40
P2RX4 Q99571 1/20 0.40
P2RX7 Q99572 1/20 0.40
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
CCR2 P41597 1/20 0.37
CCR5 P51681 1/20 0.37
FADS1 O60427 4/20 0.37
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
BRAF P15056 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
EGFR P00533 3/20 0.34
TMPRSS4 Q9NRS4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418345 1.00 TP53 (0.43) TP53MAPTSMN1; SMN2POLBP2RX1
SCHEMBL6416311 0.93 TP53 (0.42) TP53MAPTSMN1; SMN2POLBP2RX1
SCHEMBL6416319 0.93 TP53 (0.42) TP53MAPTSMN1; SMN2POLBP2RX1
SCHEMBL6415756 0.92 TP53 (0.41) TP53MAPTSMN1; SMN2POLBNPC1
SCHEMBL6415753 0.92 TP53 (0.41) TP53MAPTSMN1; SMN2POLBNPC1
SCHEMBL6435499 0.91 FADS1 (0.48) TP53MAPTSMN1; SMN2POLBNPC1
SCHEMBL6419800 0.88 TP53 (0.40) TP53MAPTSMN1; SMN2POLBNPC1
SCHEMBL6419807 0.88 TP53 (0.40) TP53MAPTSMN1; SMN2POLBNPC1
SCHEMBL6419263 0.87 MAPT (0.39) TP53MAPTSMN1; SMN2POLBHTT
SCHEMBL6419255 0.87 MAPT (0.39) TP53MAPTSMN1; SMN2POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 TP53 4485/4885MAPT 4420/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.